How Can Gastric Cancer Molecular Profiling Guide Future Therapies?

详细信息    查看全文

• 作者：Simona Corso¹ ; ^{simona.corso@unito.it" class="auth_mail" title="E-mail the corresponding author} ; Silvia Giordano¹ ; ^{silvia.giordano@unito.it" class="auth_mail" title="E-mail the corresponding author}
• 关键词：gastric cancer ; targeted therapies ; HER2 ; tyrosine kinase receptors
• 刊名：Trends in Molecular Medicine
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：22
• 期：7
• 页码：534-544
• 全文大小：2293 K

文摘

Gastric cancer is the third greatest global cause of cancer-related deaths. Despite its high prevalence, only recently have comprehensive genomic surveys shed light on its molecular alterations. As surgery is the only curative treatment strategy and chemotherapy has shown limited efficacy, new treatments are urgently needed. Many molecular therapies for gastric cancer have entered clinical trials but–apart from Trastuzumab and Ramucirumab–all have failed. We analyze the current knowledge of the genetic ‘landscape’ of gastric cancers, elaborating on novel, preclinical approaches. We posit that this knowledge lays the basis for identifying bona fide molecular targets and developing solid therapeutic approaches, requiring accurate patient selection and taking advantage of preclinical models to assist clinical development of novel combination strategies.